Rafael Holdings, Inc.(RFL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,530 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
RFL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Rafael Holdings, Inc. (RFL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RFL at 29.4/100 on a 32-signal composite quality model, placing it at rank #2,530 of 2,960 stocks — the bottom half of the AI-ranked universe. RFL scores in the top quartile across institutional flow (96.8), revenue growth (89.4). Areas of concern include revenue scale (0.3) and free cash flow (0.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Rafael Holdings, Inc. reports quarterly revenue of $179.0K, net income of $-4.2M, free cash flow of $-7.3M. Top institutional holders of RFL by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, BlackRock, based on the most recent SEC filings. RFL trades on the NYSE exchange and files with the SEC under CIK 1713863. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RFL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rafael Holdings, Inc. directly from SEC EDGAR. Rafael Holdings, Inc.'s 13F Pro composite quality score has ranged between 3 and 29 since 2021, currently 29.4 — an improving long-term trajectory across 59 quarterly and live scoring snapshots.
Revenue
Q1 2026
$179.0K
Net Income
Q1 2026
$-4.2M
Free Cash Flow
Q1 2026
$-7.3M
ROIC
Q1 2026
-36.4%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+44.0% YoYNet Income
+11.3% YoYOperating Income
+71.6% YoYEPS (Diluted)
+28.3% YoYTotal Assets
+17.8% YoYOp. Cash Flow
-142.6% YoYFree Cash Flow
-138.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $917.0K +44.0% | $637.0K +128.3% | $279.0K -32.0% | $410.0K -48.9% | $802.0K -83.7% | $4.9M |
| Net Income | $-30.5M +11.3% | $-34.4M -1734.2% | $-1.9M +98.5% | $-124.7M -440.6% | $-23.1M -114.5% | $-10.8M |
| Operating Income | $-29.2M +71.6% | $-102.6M -582.2% | $-15.0M +75.1% | $-60.5M -114.5% | $-28.2M -233.1% | $-8.5M |
| EPS (Diluted) | $-1.04 +28.3% | $-1.45 -1712.5% | $-0.08 +98.7% | $-6.31 -323.5% | $-1.49 | — |
| Total Assets | $114.1M +17.8% | $96.8M -2.0% | $98.8M -16.5% | $118.3M -23.2% | $154.1M +13.0% | $136.3M |
| Operating Cash Flow | $-18.9M -142.6% | $-7.8M +28.3% | $-10.9M +58.3% | $-26.1M -67.2% | $-15.6M -234.4% | $-4.7M |
| Free Cash Flow | $-18.9M -138.2% | $-7.9M | — | $-26.1M -65.0% | $-15.8M -204.0% | $-5.2M |
AI Insight: RFL Financial Trends
Rafael remains pre-revenue with persistent operating losses; cash burn stabilizing but debt emerged in Q4 2025.
• Net losses moderated to $4M–$6M in recent quarters (Q2 2026), down from $12M peak in Q3 2025.
• Operating cash outflow averaged $2M–$3M in first half 2025, worsened to $7M–$10M in latter half.
• Equity declined from $94M (Q3 2025) to $75M (Q2 2026) as accumulated losses eroded shareholder value.
⚠ $22M debt appeared in Q4 2025 balance sheet; monitor covenant compliance and cash runway.
⚠ Zero revenue across all eight quarters signals extended clinical/regulatory pathway; no near-term inflection visible.
AI Insight: RFL Ratio Trends
Rafael Holdings remains deeply unprofitable with all efficiency metrics sharply negative; modest recent improvement in ROE and ROA masks persistent capital destruction.
• ROE improved from -51.2% in Q3 2025 to -22.4% in Q2 2026, suggesting recent operational stabilization.
• ROIC remains deeply negative across entire period; Q2 2026 at -28.3% reflects continued value destruction.
• Leverage stable: D/E ratio 0.26–0.29 over last four quarters, avoiding balance-sheet deterioration.
⚠ ROA volatility extreme: swung from -42.4% (Q3 2025) to -18.4% (Q2 2026)—signals underlying operational instability.
⚠ No positive profitability metrics visible across 18-month window; path to breakeven unclear.
Get alerted when RFL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Rafael Holdings, Inc. including:
Top Institutional Holders of RFL
VANGUARD CAPITAL MANAGEMENT LLC
$4.5M1,365,997 shGEODE CAPITAL MANAGEMENT, LLC
$1.4M429,879 shBlackRock, Inc.
$1.3M390,068 shDIMENSIONAL FUND ADVISORS LP
$914.7K278,910 shVANGUARD FIDUCIARY TRUST CO
$677.4K206,521 shIEQ CAPITAL, LLC
$541.1K164,963 shSTATE STREET CORP
$515.8K157,270 shJANE STREET GROUP, LLC
$369.7K112,720 shCITADEL ADVISORS LLC
$343.1K104,600 shWELLS FARGO & COMPANY/MN
$339.8K103,590 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $4.5M | 1,365,997 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.4M | 429,879 |
| BlackRock, Inc. | $1.3M | 390,068 |
| DIMENSIONAL FUND ADVISORS LP | $914.7K | 278,910 |
| VANGUARD FIDUCIARY TRUST CO | $677.4K | 206,521 |
| IEQ CAPITAL, LLC | $541.1K | 164,963 |
| STATE STREET CORP | $515.8K | 157,270 |
| JANE STREET GROUP, LLC | $369.7K | 112,720 |
| CITADEL ADVISORS LLC | $343.1K | 104,600 |
| WELLS FARGO & COMPANY/MN | $339.8K | 103,590 |
Companies Similar to RFL
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Butterfly Network, Inc.
Inhibrx Biosciences, Inc.
Altimmune, Inc.
Tonix Pharmaceuticals Holding Corp.
Editas Medicine, Inc.
Upstream Bio, Inc.
TScan Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put RFL on your watchlist
Track score changes the day Rafael Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RFL a good stock to buy?
13F Pro's AI-powered analysis of Rafael Holdings, Inc. (RFL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RFL are available on the RFL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RFL is classified as a small company.
Which hedge funds own RFL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RFL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rafael Holdings, Inc.'s investment landscape.